HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
1 published article · Updated continuously
7 trials tracked for polypoidal choroidal vasculopathy: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 314 citations.
Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Ranibizumab treatment for polypoidal choroidal vasculopathy (PCV) demonstrated significant improvements in visual outcomes. Patients showed a mean increase of 8.3 letters in Best Corrected Visual Acuity (BCVA) at 12 months (p<0.001), with 115 patients achieving complete polyp regression by that same time point (p<0.0001) 1.
Aflibercept is established as an intervention for PCV, with studies evaluating both standard administration and a 'Treat and Extend' regimen [2, 3]. Clinical data for aflibercept showed a mean improvement of 9 letters in visual acuity from baseline to 12 months, with 87.5% of patients losing fewer than 15 letters and 95% maintaining a visual acuity of at least 20/200 3.
Verteporfin Photodynamic Therapy (PDT) was evaluated for PCV, with results showing that 15, 18, and 9 participants achieved at least one complete polyp regression during a 6-month period as assessed by ICGA 4.
AI synthesis of 6 cited trials, updated Oct 5, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.